eCourse
Therapeutic Advances in Metastatic HER2-Positive Breast Cancer
Release Date: December 16, 2020
Expiration Date: December 15, 2021
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
program overview
Program Description
Several novel agents, including antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors, are approved or in development for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Although recent approvals have led to substantial improvements in disease control and overall survival, selection and sequencing of agents, along with identification and management of therapy-associated toxicities, often remains a challenge. This program addresses the range of new agents that are available and in development, their recommended use in clinical practice, and strategies for management of adverse events (AEs) and patient education.
Format
Interactive, audio-enhanced slide lecture
Learning Objectives
After completing this activity, participants should be better able to:
- Assess the latest safety and efficacy data for new and emerging therapies for patients with HER2-positive breast cancer
- Identify evidence-based treatment approaches for individual patients with HER2-positive breast cancer
- Utilize strategies for the prompt recognition and mitigation of AEs associated with new and emerging therapies for HER2-positive breast cancer
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Sara M. Tolaney, MD, MPH
- Assistant Professor of Medicine
- Harvard Medical School
- Associate Director
- Susan F. Smith Center for Women’s Cancers
- Director
- Clinical Trials, Breast Oncology
- Director
- Breast Immunotherapy Clinical Research
- Dana-Farber Cancer Institute
- Boston, Massachusetts
Corinne Williams, PA-C
- Physician Assistant
- Division of Hematology-Oncology
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Northwestern University Feinberg School of Medicine
- Chicago, Illinois
- Immediate Past President
- Association of Physician Assistants in Oncology
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
CNE course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until December 15, 2021. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity was developed from a series of programs cosupported by educational grants from Astellas and Pfizer; Bayer HealthCare Pharmaceuticals Inc.; Bristol-Myers Squibb; Daiichi Sankyo, Inc.; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; Oncopeptides; Sanofi Genzyme; and Seattle Genetics, Inc.
This activity is supported by educational grants from Daiichi Sankyo, Inc. and Seattle Genetics, Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Tolaney: advisory board: Celldex, G1 Therapeutics, Kyowa Kirin, Puma Biotechnology, Samsung Bioepis, Silverback Therapeutics; advisory board/consultant/PI: AstraZeneca, Bristol-Myers Squibb, Eisai, Lilly, Merck, Nanostring, Nektar Therapeutics, Novartis, Pfizer; advisory board/PI: Genentech/Roche, Immunomedics, Sanofi; consultant: AbbVie, Athenex, Daiichi Sankyo, Oncopeptides, Seattle Genetics; consultant/PI: Odonate Therapeutics; PI: Cyclacel, Exelixis; steering committee: CytomX Therapeutics.
Ms Sandy: speakers bureau: AstraZeneca, Merck, Takeda.
Ms Williams: speakers bureau: AstraZeneca.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Watch the eCourse in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: December 16, 2020
Expiration date: December 15, 2021
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 98220O-7D